Report cover image

Middle East and Africa Biobanking Market Report and Forecast 2024-2032

Publisher Expert Market Research
Published Jun 26, 2024
Length 140 Pages
SKU # EMAR18971421

Description

Middle East and Africa Biobanking Market Report and Forecast 2024-2032


Middle East and Africa Biobanking Market Report and Forecast 2024-2032

Middle East and Africa Biobanking Market Size

The global biobanking market was valued at USD 72.1 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the growing prevalence of chronic diseases and the rising advancements in biobanking technologies. It is expected to grow at a CAGR of 5.90% during the forecast period of 2024-2032, with the values likely to attain USD 131.1 billion by 2032.

Middle East and Africa Biobanking Market Outlook
  • Biomedical research, which facilitates the development of new and effective treatments, is required to tackle the rising burden of chronic diseases in the region. The growing emphasis on biomedical research activities is expected to drive market demand.
  • One of the major Middle East and Africa biobanking market trends is the rising investments in the establishment of technologically advanced biobanking facilities. In May 2022 , the Al Jalila Foundation announced an investment of USD 4.6 million to establish the first robotic biobank in the United Arab Emirates, in collaboration with other organizations to advance medical research.
  • The market share is also influenced by the increasing focus on the development of personalized medicine. In September 2023 , it was reported that Abu Dhabi is set to launch a biobank for human stem cells and tissues with the aim of boosting personalized medical research.
Middle East and Africa Biobanking Market Analysis

Biobanking involves the process of collecting, processing, and storing biological samples such as blood, tissue, and DNA. It offers essential resources for medical researchers to study disease mechanisms and individual responses to treatments and thus, is crucial for the development of personalized medicine. Biobanks in the Middle East and Africa region are increasingly contributing to the diversification of genetic and health data, which has been heavily skewed towards Western populations , thereby supporting the advancement of the global biobanking market . Further, the rise in the prevalence of chronic diseases like cancer, diabetes, and cardiovascular conditions which requires extensive biomedical research to develop effective treatments is expected to propel the Middle East and Africa biobanking market growth in the forecast period.

One of the major market trends is the rising investments in the establishment of advanced biobanking facilities to accelerate medical discoveries. For instance, in May 2022 , the Al Jalila Foundation (a member of the Mohammed Bin Rashid Al Maktoum Global Initiatives) announced that it would establish the first robotic biobank in the United Arab Emirates, in collaboration with the Dubai Health Authority (DHA) and the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) to drive medical research in the areas of genetic disorders, chronic diseases and pandemics. Scheduled to be open in 2024 , the foundation has invested USD 4.6 million in building the biobank that manages seven million human biological samples and uses an automated, robotic, artificial Intelligence-based system to secure the samples in cryogenic storage. Such substantial investments in technological improvement in biobanking practices are likely to elevate the Middle East and Africa biobanking market value.

The market share is also influenced by the growing impetus for the development of personalized medicine. In September 2023 , it was reported that Abu Dhabi is set to launch a biobank for human stem cells and tissues with the aim of boosting personalized medical research. This proposed project, presented by the Department of Health – Abu Dhabi and approved by the Crown Prince of Abu Dhabi, is poised to support research that will leverage advanced technology and scientific methods to advance the treatment of over 80 diseases, including cancer and blood disorders. The increased government initiatives aimed at enhancing healthcare outcomes are anticipated to bolster market share of biobanking in coming years.

Middle East and Africa Biobanking Market Segmentation  

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product and Service

Equipment

Consumables

Service

Software

Market Breakup by Application

Regenerative Medicine

Life Science Research

Clinical Research

Market Breakup by Sample Type

Blood Tissue

Nucleic Acids

Cell Lines

Market Breakup by End User

Academic Institutions

Pharma and Biotech Companies

Market Breakup by Country
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Leading Players in the Middle East and Africa Biobanking Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • PHC Holdings Corporation
  • Thermo Fisher Scientific, Inc.
  • Becton, Dickinson and Company
  • QIAGEN N.V.
  • Merck KGaA
  • Avantor, Inc.
  • Cryoport, Inc.
  • Tecan Trading AG
  • Lifecode Technologies Pte Ltd
  • Azenta, Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs
  • What is the Middle East and Africa biobanking market forecast outlook for 2024-2032?
The Middle East and Africa biobanking market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 6.89% during the forecast period of 2024-2032 and is likely to reach a market value of USD 131.1 billion by 2032.
  • What are the major factors aiding the Middle East and Africa biobanking market demand?
The rising burden of chronic diseases and the growing demand for precision medicine are fuelling the demand for the market.
  • What are the major Middle East and Africa biobanking market trends?
One of the significant trends in the market is the rising investments in the establishment of technologically advanced biobanking facilities. In May 2022, the Al Jalila Foundation, in collaboration with other organizations, announced an investment of USD 4.6 million to establish the first robotic biobank in the United Arab Emirates.
  • What is the market segmentation based on the product and services?
Based on the products and services, the market is segmented into equipment, consumables, services, and software.
  • What is the market breakup by sample type?
By sample type, the market is divided into blood tissue, nucleic acids, and cell lines.
  • What are the major end users of biobanking?
End users of the market are academic institutions, pharma, and biotech companies.
  • What are the applications of biobanking?
Major applications areas include regenerative medicine, life science research, and clinical research.
  • What is the market segmentation by countries?
The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.
  • Who are the key players involved in the Middle East and Africa biobanking market?
The key players in the market are PHC Holdings Corporation, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, QIAGEN N.V., Merck KGaA, Avantor, Inc., Cryoport, Inc., Tecan Trading AG, Lifecode Technologies Pte Ltd, and Azenta, Inc.

Meta description

The Middle East and Africa biobanking market is poised for growth, driven by the expansion of the global market, which was valued at USD 72.1 billion in 2023 and is projected to grow at a CAGR of 6.89% during the forecast period of 2024-2032.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

Table of Contents

140 Pages
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Middle East and Africa Biobanking Market Overview
3.1 Middle East and Africa Biobanking Market Historical Value (2017-2023)
3.2 Middle East and Africa Biobanking Market Forecast Value (2024-2032)
4 Middle East and Africa Biobanking Market Landscape*
4.1 Middle East and Africa Biobanking: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Middle East and Africa Biobanking: Product Landscape
4.2.1 Analysis by Product and Service
4.2.2 Analysis by Application
5 Middle East and Africa Biobanking Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Middle East and Africa Biobanking Market Segmentation (2017-2032)
6.1 Middle East and Africa Biobanking Market (2017-2032) by Product and Service
6.1.1 Market Overview
6.1.2 Equipment
6.1.3 Consumables
6.1.4 Service
6.1.5 Software
6.2 Middle East and Africa Biobanking Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Regenerative Medicine
6.2.3 Life Science Research
6.2.4 Clinical Research
6.3 Middle East and Africa Biobanking Market (2017-2032) by Sample Type
6.3.1 Market Overview
6.3.2 Blood Tissue
6.3.3 Nucleic Acids
6.3.4 Cell Lines
6.4 Middle East and Africa Biobanking Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Academic Institutions
6.4.3 Pharma and Biotech Companies
6.5 Middle East and Africa Biobanking Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 Saudi Arabia
6.5.3 United Arab Emirates
6.5.4 Nigeria
6.5.5 South Africa
6.5.6 Others
7 Saudi Arabia Biobanking Market (2017-2032)
7.1 Saudi Arabia Biobanking Market (2017-2032) by Product and Service
7.1.1 Market Overview
7.1.2 Equipment
7.1.3 Consumables
7.1.4 Service
7.1.5 Software
7.2 Saudi Arabia Biobanking Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Regenerative Medicine
7.2.3 Life Science Research
7.2.4 Clinical Research
7.3 Saudi Arabia Biobanking Market (2017-2032) by Sample Type
7.3.1 Market Overview
7.3.2 Blood Tissue
7.3.3 Nucleic Acids
7.3.4 Cell Lines
7.4 Saudi Arabia Biobanking Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Academic Institutions
7.4.3 Pharma and Biotech Companies
8 United Arab Emirates Biobanking Market (2017-2032)
8.1 United Arab Emirates Biobanking Market (2017-2032) by Product and Service
8.1.1 Market Overview
8.1.2 Equipment
8.1.3 Consumables
8.1.4 Service
8.1.5 Software
8.2 United Arab Emirates Biobanking Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Regenerative Medicine
8.2.3 Life Science Research
8.2.4 Clinical Research
8.3 United Arab Emirates Biobanking Market (2017-2032) by Sample Type
8.3.1 Market Overview
8.3.2 Blood Tissue
8.3.3 Nucleic Acids
8.3.4 Cell Lines
8.4 United Arab Emirates Biobanking Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Academic Institutions
8.4.3 Pharma and Biotech Companies
9 Nigeria Biobanking Market (2017-2032)
9.1 Nigeria Biobanking Market (2017-2032) by Product and Service
9.1.1 Market Overview
9.1.2 Equipment
9.1.3 Consumables
9.1.4 Service
9.1.5 Software
9.2 Nigeria Biobanking Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Regenerative Medicine
9.2.3 Life Science Research
9.2.4 Clinical Research
9.3 Nigeria Biobanking Market (2017-2032) by Sample Type
9.3.1 Market Overview
9.3.2 Blood Tissue
9.3.3 Nucleic Acids
9.3.4 Cell Lines
9.4 Nigeria Biobanking Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Academic Institutions
9.4.3 Pharma and Biotech Companies
10 South Africa Biobanking Market (2017-2032)
10.1 South Africa Biobanking Market (2017-2032) by Product and Service
10.1.1 Market Overview
10.1.2 Equipment
10.1.3 Consumables
10.1.4 Service
10.1.5 Software
10.2 South Africa Biobanking Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Regenerative Medicine
10.2.3 Life Science Research
10.2.4 Clinical Research
10.3 South Africa Biobanking Market (2017-2032) by Sample Type
10.3.1 Market Overview
10.3.2 Blood Tissue
10.3.3 Nucleic Acids
10.3.4 Cell Lines
10.4 South Africa Biobanking Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Academic Institutions
10.4.3 Pharma and Biotech Companies
11 Regulatory Framework
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication Year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by Departments
13.7 Analysis by Recipient Organization
14 Funding and Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1 Market Share by Top 5 Companies
16.2 PHC Holdings Corporation
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Thermo Fisher Scientific, Inc.
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Becton, Dickinson and Company
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 QIAGEN N.V.
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Merck KGaA
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Avantor, Inc.
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 Cryoport, Inc.
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Tecan Trading AG
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Lifecode Technologies Pte Ltd
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Azenta, Inc
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
17 Middle East and Africa Biobanking Market – Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us